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Surflt¢,~ interleukin.6 receptors, were idemilled on human polymorl~hUnuclear I©ukoeyte~ (PMNL} by monoclonal anti p~0.~:hain antibody MT ll~ 
Cytopbtsmic RNA harvested From PMNL also contained IL.6.R tr=mr~ript~, Itindin$ of recombinant human (rh) interleukin.6 (11.-6} to IL,6.R 
bearintl PMNL was, identified by Ilowcytomctry usintl ph~eoerytltrin (PE)-conjujatcd lijand, Treatment ofPMNL with rh//.r~mulocyt¢.macroplt=lB~ 
colony.=climulatinl~t factor (GM.CSF) led to the inability of PMNL to bind MT I1~ monoclona| ntibody (moAb) and to display binding site~ for 
PE-¢onjug-'~ted rh IL.6, l=~vels of IL.6.R transcripts inPMNL exposed to GM.CSF were aboa| .~.fold t~low those of PMNL cultured in rneditm; 
only, Though a definitive role for IL-6 to modulate the function of PMNL w~ts not found, treatment ofPMNL with rh IL-6 clearly resulted in
an enh=Lncement of Iranscript levels of the e~trly response tlenes ¢-fo.~ lind ¢.jun in these cells, thus indicatinl~ that IL.6 bindinf, is followed by sit, hal 
tr=msduction, 
Neutrophii; IL-6 receptor; GM-CSF; Receptor downre~ulation 
I. INTRODUCTION 
lnterleukin.6 is one of  the central mediators of  the 
complex reaction of  the host to injury or infection 
referred to as the acute phase response ([1,2] for 
review). Important sites of" IL-6 synthesis include 
monocytes, blood vessel endothelials, smooth muscle 
cells, connective tissue fibroblasts, chondrocytes, 
osteoblasts, keratinocytes, mesangial cells, astrocytes, 
anterior pituitary cells, and stromal endometrium cells 
([3] for review). We have recently shown that PMNL 
may also be able to produce IL-6, upon activation with 
GM-CSF or tumor necrosis factor [4]. The physiologi- 
cal ef,fects exerted by IL.6 include induction of fever, 
induction of immunoglobulin synthesis in activated B- 
cells, activation of T-cells and natural killer cells, 
stimulation of  megakaryopoiesis, induction of acute 
phase response synthesis by the liver, and corticotropin 
release by cells of  the pituitary gland ([3] for review), 
IL-6 acts on its target cells via a specific dimeric recep- 
tor. A 80 kDa membrane protein serves as IL-6 binding 
site [5]. IL-6 binding is followed by association of the 
80 kDa protein with a second 130 kDa transmembrane 
protein providing signal transduction [6]. Given the 
previous demonstration by several investigators, in- 
eluding ourselves, of biosynthetic activity of  human 
PMNL upon exposure to cytokines [4,7-9], and the 
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abundant presence of PMNL in many organs partici- 
pating in the acute phase reaction, we thought o deter- 
mine whether IL-6 was also able to act on, PMNL. To 
that end, IL-6-R expression and IL-6 binding by PMNL 
was explored, A series of other cytokines involved in 
acute phase responses were also investigated to address 
their possible role in modulating IL-6 receptiveness of
PMNL,  
2, MATERIALS  AND METHODS 
2. I, Purification of  PMNL 
PMNL were separated from heparinized peripheral b ood obtained 
from consenting healtlW volunteers by density separation ustng 
Ficoll.Hypaque (Pharmacia Laboratories, Uppsala, Sweden), follow- 
ed by dextran sedimentation as previously described [4]. Culture of 
PMNL was performtd in serttm-free culture medium prepared as 
outli ned below. 
2,2, Preparatiotl of  serum-free culture medium 
Serum-free culture medium was prepared from powdered lscove's 
modified Dulbecco's medium (IMDM) (Gibed, Grand Island, NY), 
To 900 hal of reconstituted IMDM triple.destilled water (40.5 ml), 
sodium bicarbonate (3.0 mg/ml), 3.mercapto-l,2.propanediol 
(8/~g/ml), penicillin (100U/rnl), and streptomycin (100t~g/ml; 
Sigma Chemicals, Munich, Germany) were added. Five ml of 10% 
fatty acid.free deionized bovine serum albumin was added to 
44,35 ml of prepared IMDM, To this mi×ture was added 0.65 ml 
transferrin (90 mg/ml) saturated with 7.0 mmol/l ferric chloride in 
1 mmol/l HCI (Sigma) [10], 
2,3. Monoclonal antibodies atld cytokines 
MoAb MTI8 detecting the pg0 iL-6-R chain was obtained from T. 
Hirano (Biomedical Research Center, Osaka University, Osaka, 
Japan) [1 l] Anti-CD-16 moAb were purchased from Becton Dickin- 
Published by Elsevier Science Publishers B, It, 47 
Volume 2~13, number I FEI~S L~TTEkS M~ty 1991 
son (Heidelberlh C~ernlany), and tncluded pl~p~t~cr~'thrlnrconj~tt~led 
~li.L~u. lit: (done It 73, I ) and iquores¢~tnazed ,fitt.lxu. I 1 ~ ((:lone 
NKP I$). Phy¢oerylhrfn.~:onjnl!ated rh  IL,6 anti th IL .~ were p~r- 
t:hased from Br|tlsh [~io-T¢~hnology (Cowley, o,xrord, UK). Re¢om, 
binam hum~tn IL-:~ ¢md GM.CSF were kindly provided by lmmu.¢~ 
(Seat|le. WA) #nd were obl~ined throullh D. Krum,,~qeh (P, el~rinp 
w,~'k¢ AG, Marburg, Germany), Recombinant human m~rophalt~e 
(M).CSF and leukemia inhibitory fat:mr (LIF) were tdrts or M, Gar. 
nick and G, Wonl~ (Genetics Institute, C=ambridlle, MA). Recombi- 
nant human i!ranulocyo= (¢I).CSF w~s kindly doIr'laled by L. SOt|~¢I 
(Aragon, Thousant. Oaks. CA), Ret:omblnant human IL-4 wa~ a ~if| 
of P, Trotla (Schcring Corp,, Bloomfidd, N J), 
2,4, hnmunOflttorescenee m~u/ysLs 
10 ~ PMNLiml in serum,free culture medium were eilher cultured 
for the indicated period of time prior to immunofluorest:ence analysis 
or were directly subjet:ted to flow cytonte|rlt: ree.color intnluno. 
fluorescence using FACS Star flow t:Ytontet~r [121 (Itecton Dickin- 
son), Staittiall with MT 18 moAb was done witt~ "~5 xg antibod~'/ml 
or phosphate-buffered saline (PBS; Gibco) for 30 rain, that was 
followed by an incubation (30 rain) with fluorest:einn(ed 8oat anti. 
mouse IgG (Bet:ion Dickinson)at 20 l, glml, Int:ub~tion with anti.CD 
16-PE and fluoresceinated anti.CD 16 (2~,t~/ml} was also done for 
30 rain. Negative nonbinding control antibodies ased at 8:S0pg/ml 
each included lluoresceinated -- or PE - conju[F~led mouse lgG= or 
IgG~,,.h (Bee(on Dickinson), The concentration of IL.~.PE to be used 
for staining of 10 ~ PMNL was I00 ng/ml, In experiments analyzing 
IL.6 binding, a 10X concentrated PBS was used for washing pro. 
cedurcs to ndnimize background and enhance spt~cifie binding, 
2.5. Isolation of  RN,,I. cDN.,I probes, RNA hie(ring 
Total RNA was extracted after lysis of cells in guanidinium isot hie. 
cyanate followed by separation on a cesium chloride gradient [13], 
RNA was electrophoresed on denaturing formaldehyde gels and blot. 
ted onto nylon membranes (Nytr~n; Schleicher & Schuell, Dassel, 
Germany), Prehybridization was carried out at 42*C in the presence 
of 5 × SSC (1 × SSC = 0,15 molll NaCI, 0,015 mol/I sodium 
citrate), 500/o formamide, I% Na2DoSH,h 5 × Denhardt's olution 
and 100 ag/ml denatured sonicate~ salmon sperm DNA, Hybridiza. 
lion was performed using oligolabeled [14] eDNA probes. The IL-6R 
eDNA probe was a 1,7 kb Hitldlll/Xbul fragmenl purified from tl~e 
pBSF2R,236 plasmid kindly provided by T, Hirano [5]. The 800.bp 
BamHl/Pstl fragment of a human a,-actin eDNA (pAC 289) was 
kindly provided by J, Ramadori (Department of Medicine, Universi- 
ty of Mainz, Germany) [16], The 1,2 kb Ec'oRIt'BavnHI fragment 
[16] of human c.jun in p.Bluescript SK was provided by P. Angel 
(Dept of Pharmacology, University' of California; San Diego, CA), 
The 900 bp Ncol/Scal fragment of human c.fos in pBR322 was pur- 
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Fig, 2, Northern blots analyzing expression of IL.6-R transcripts in 
PMNL (lane I). For control of size of IL.6.R mRNA (4,8 kb), 
cytoplasmic RNA obtained from blood monot:ytes were also 
hybridized with the IL.6.R specific eDNA (lane 2). Each lane 
contains 20/~g RNA, Experimen,:s with PMNL from two different 
donors (not shown) gave identical results 
chased from the American Tissue Type Culture Collection (Rock. 
ville, MD) [17]. Hybridization took plate at 420C in the presence of 
2 x SSC. 50% formamide, IO/o Na~DoSH~, 10% dextran st, lfate, 5 
x Denhardt's olution, 100 ~g/ml denatured salmon sperm DNA, 
and probe labeled to high specific activity (I x 10 ~ cpm/ml I~ybridiza- 
tion mixture), Filters were washed in decreasing concentrations of
SSC at 65"C to final stringency ofO.l x SSC for 15 rain and exposed 
to X.AR5 X-ray film (Kodak, Rochester, NY) at -70% using intensi- 
fying screens, 
3, RESULTS 
Pur i f i ca t ion  o f  PMNL y ie lded  preparat ions  conta in -  
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Fig, I, Two-color fluorescence analysis of PMNL expressing CDI6 (moAb anti-Leu-I lc) and IL-6-R (moAb MT 18), The left panel represents 
negative controls using irrelevant non-binding PE-, or fluorescein-conjugated antibodies. The right panel shows staining of PMNL with IL-6-R 
moAb (log green fluorescence) and CD16-PE (log red fluorescence), The upper right chart of this panel represents PMNL that are doable stained 
with both moAb. The data show a representative experiment, Three furtl~er experiments with PMNL from different donors gave identical results, 
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in= 88-92% neutrophils, 0-8% eoslnophils, O-]~0 
basophils and 0-1% mostly ~ranular lymphocytes by 
morphology. This cell population was analyzed for sur- 
lace expression of the p80 chain of the IL-6-R using 
two.color Fluorescence flow cytometry employing 
moAb anti.MT 18 and anti-CD 16-PE. As shown in 
Fig, !, more than 92~e of cells expressing CD 16-PE 
were also stained with ant i .MT 18 suggesting IL.6-R ex. 
pression by PMNL To further assess binding sites for 
lL,6 on the surface of  PMNL,  cells were analyzed using 
PE-conjugated rh IL.6 and fluoresccin-conjugated 
anti-CD-16 moAb,  demonstrating that almost all CD 
16 positive PMNL bound IL-6. Two-color immune- 
fluorescence analysis with PE-conjugated 11.-6 and 
fluoresceinated MT 18 moAb gave identical results (not 
shown). Northern blot analysis of cytoplasmic RNA 
obtained from freshly separated PMNL using an 
IL-6-R specific eDNA disclosed IL-6-R transcripts 
1 2 
A 
(Ft=, 2), Evidence for receptiveness of PMNL for rh 
IL-6 was further substantiated by demonstrating that 
culture of  PMNL for 4 h in the presence o f  rh IL-6 
(20 nglml) was able to enhance transcript levels of the 
early response genes c.fos and c-jun known to form the 
transcriptlor~ factor AP-I (Fig. 3), but had no effect on 
mRNA acct=mulation of the IL-6-R in cultures per- 
formed over a period of 24 h (Fig, 4). Levels of IL-6.R 
transcripts were also monitored upon exposure of  
PMNL (12-24 h) to other cytokines including GM- 
CSF (2Ong./ml), G-CSF (20 ng/ml), M-CSF (1000 
U/ml), IL-3 (20nglml), lL.4 (50 ng/ml), LlF (tO0 
Ufml),  and lL-8 (50 ng/ml). As shown in Fig, 4, treat- 
ment of PMNL with GM-CSF, but not with the other 
cytokines, led to decrease of IL.6-R mRNA. Den- 
sitometric analysis of autoradiograms after normaliza- 
t ion for c~-actin transcripts showed that GM-CSF 
mediated ecrease of IL.6-R mRNA was 5-fold (not 
shown), Given this observation, we next examined the 
effects of GM-CSF on binding of MT 18 moAb and 
PE-conjugated IL-6 to PMNL (Fig. 5), After treatment 
with rh GM-GSF for 2 h, PMNL failed to display 
detectable IL-6-R. Similarly, exposure of PMNL to rh 
IL-6 (20 ng/ml) for only 30 rain led to an almost com- 
plete disappearance of binding sites for MT 18 an- 
t ibody (Fig. 6), but had no effect on levels of  IL-6-R 
mRNA (at 12--24 h; Fig. 4), 
B 
C wd ip  
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Fig. 3, Northern blots analyzing the effect of rh IL-6 treatment of
PMNL on transcript levels of c.fos (panel A), C-jill1 (panel B) IL-6-R 
(panel C) -and ~-actin (panel D). PMNL were cultured in tl~e presence 
(lane 2) m' absence (medium control; lane 1) of rh tL.6 (20 ng/mI). 
Thereafter cytoplasmic RNA was collected and sequentially h bri- 
dized with specific eDNA probes, Culture time was either 4 h (for 
detection of c~fos and c-jun transcripts) or 12 h (for detection of 
IL-6-g mRNA), 20/,8 RNA was loaded in each lane, a-Actin 
hybridization controls comparable RNA loading in single lanes. Lane 
'a' represents actin levels after 4 h of culture, lane 'b' shows actin 
levels obtained after 12 h of cultures. Experiments with PMNL from 
two different donors gave identical results (not shown). 
G-CSF 
M=CSF 
IL-3 
IL-4 
IL-8 
LIF 
Medium 
GM-CSF 
I 
Fig, 4. Northern blots analyzing the effect of various cytokines on 
IL-6-R transcript levels, PMNL were xposed to various cytokines as 
indicated, or were exposed to medium only, After 12 h of culture 
cytoplasmic RNA was collected and subjected toanalysis for IL-6-R 
mRNA, Cultures were also performed over a period of 24 h and gave 
comparable r sults (not shown), Integrity of RNA and identical RNA 
loading in single lanes was confirmed by ethidium bromide staining 
of ribosoxnal (r) RNA, Arrows indicate 28 S and 18 S rRNA, 
Experiments vcith PMNL from another donor gave identical results 
(not shown), 
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Itiili I 
log green fluorescence log green fluorescence 
Fig, :5, Efrc~:t of rh GM.CSF treatment (2 I~) on IL.6-R expression (moAb MT 11t) by CDI6 positive PMNL, The left panel shows lwo.¢olor 
fluorescence analy=is of PMNL with MI' 18 moAb (Io8 ~reen fluorescence) nnd and.CDI6.PE (Io~ red fluorescence) =~fter culture= in the pre~enee 
of rh GM.CSF, In the rilthl panel the scmle analysl~ was performed with PMNL exposed for a perlod o1' 2 h to medium only, 'l'he effect of exposure 
of PNINL Io GM.CSF wa~ aRo amdy~ed after 30 ntln and 60 mitt of culture, bu~ r+tiled to reveal ¢ttanlles in MT 18 surface xpression (nol ~hown), 
The tlma ~ho~ a representative cxperintenh Three further experlmenl~ with PMNL front different donor~ l=~ave identical resuh~ (not shown), 
~{ a 10 g 1~2 1~ a t~ 
log green fluorescence 
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Fig, 6, Effect of rh It.-6 treatment (30 rain) on IL-6-R expression (moAb MT 18) by CDI6 positive PMNL: For protocol see legend to Fig. 5. 
Experiments with PMNL front another donor gave identical results (not shown). 
4. DISCUSSION 
We describe the presence of functional receptors for 
IL-6 on the surface of human polymorphonuclear 
leukocytes. PMNL exhibit levels of IL-6-R mRNA 
detectable by Northern blot analysis of cytoplasmic 
RNA, express urface binding sites for monoclonal an- 
tibody MT 18, known to identify the signal transducing 
pS0 chain of the IL-6-R [19], and bind recombinant 
human IL-6. Exposure of PMNL to IL-6 results m in- 
creases in levels of transcripts of the early response 
genes c-los and c-jun, forming the transcription factor 
AP-1. AP-I binding sites are present in promoter/ 
enhancer sequences of many regulatory genes [18]. 
There is thus indirect evidence to assume a fundamental 
role for IL-6 in PMNL function. In this regard we have 
analyzed the effects of IL-6 on superoxide anion 
production and the migration behavior of PMNL (data 
not shown), but failed to detect changes in both chemi- 
luminescence and Boyldon chamber assays. Unlike in 
rnonocytes where IL.6 causes downregulation of 
IL-6-R mRNA [19], IL-6 treatment of PMNL failed to 
50 
alter IL.6-R transcript levels. Exposure of PMNL to rh 
GM-CSF, however, led to decreased levels of stable 
IL-6-R transcripts, that was not observed when the ef- 
fects of other cytokines including G-CSF, M-CSF, 
IL-3, IL-4, IL-8, and LIF were investigated. Mechan- 
isms of down'modulation f IL-6-R transcripts by GM- 
CSF are still unknown and need further investigation. 
Nevertheless, we also observed an almost complete 
disappearance of IL-6 surface binding sites on PMNL 
as early as 2 h after initiation of cultures with GM- 
CSF. It is presently unclear whether upon GM-CSF 
exposure surface IL-6-R will internalize or will be 
shedded into the external environment. In preliminary 
experiments, not shown here, we failed to detect ad. 
sorbence of IL-6 by culture supernatants of GM-CSF 
treated PMNL, thus suggesting that GM-CSF treat- 
ment may not have caused shedding of IL-6-R. On a 
speculative basis one might assume that secretion of 
IL-6 by GM.CSF treated PMNL may have caused 
IL-6-R down-modulation. Time kinetics by which 
IL-6-R down-modulation in GM-CSF stimulated 
PMNL was observed support his hypothesis. Whereas 
Vohzme 283, number | FEB$ LETTERS M~y I~r l  
in IL.6 tremcd cells ]L-6.R dis~ppcared already ~s carl), 
~s 30 rain after |nili~zion of c~hnre, GM-CSF  zrc~|. 
menz req.ir~d ~[ leasz 2 h to down.resuln[e IL.6 
binding ~nd [L-6-R s~rf'~ce expression, hnpllcalion ot~ 
~hzzz interp~ezation would be zha¢ GM.CSF  induces IL.6 
~ulocrinism. 
~4ck~tJ+~ledl~emenl~: S ipport¢d b~t ll~e Deutsche FQrsehun~s~¢. 
m¢insch~tfz (to R.H,} lind The Dr Mildred Sche¢l.Siifiunzl (to M,B. 
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